Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119362 | 0.82 | PDE5A (0.40) | ESR1PDE5AAPPPDE2ACHUK | |
| SCHEMBL20119714 | 0.82 | VNN1 (0.42) | ESR1PDE5AAPPCNR1 | |
| SCHEMBL20119651 | 0.78 | APP (0.44) | ESR1PDE5AAPPPDE2ACNR1 | |
| SCHEMBL20119666 | 0.72 | SMN1; SMN2 (0.57) | — | |
| SCHEMBL20119892 | 0.71 | KCNH3 (0.43) | PDE2ACCNE1CDK2SRC | |
| SCHEMBL20119883 | 0.70 | PDE5A (0.40) | ESR1PDE5AAPPCHUKTMIGD3 | |
| SCHEMBL20344048 | 0.69 | PDE5A (0.52) | ESR1PDE5AAPPCHUKCDK2 | |
| SCHEMBL20119563 | 0.69 | HRH4 (0.36) | ESR1 | |
| SCHEMBL20119884 | 0.68 | ESR1 (0.44) | ESR1PDE5AAPPCHUK | |
| SCHEMBL1018453 | 0.67 | CHUK (0.39) | CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | ESR1 4474/4885PDE5A 3202/4885APP 604/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | ESR1 4474/4885PDE5A 3202/4885APP 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.